Latham’s award-winning life sciences IP practice works at the cutting edge of pharmaceutical and biotechnology patent, trade secrets, and brand-on-brand competitor litigation.
We offer life sciences companies a deep bench of patent litigators, many of whom hold advanced degrees in chemical or life sciences, as well as a team of PhD-holding technical analysts and former Federal Circuit clerks with significant experience litigating pharmaceutical cases. Our representations of innovator companies begin with us analyzing client patents and mastering the underlying science. Our lawyers and analysts are well-versed in all forms of life sciences patent and trade secrets litigation, from brand-on-brand biologic disputes, to matters involving vaccines, biosimilars, CRISPR, CAR-T, gene therapy, and diagnostics and manufacturing processes.
We represent many of the world’s leading innovative pharmaceutical companies in Hatch-Waxman litigation, regularly enforcing and defending patents that protect products with billions of dollars in annual sales.
Patent challenges by generic drug manufacturers are a persistent issue for branded pharmaceutical companies. We bring extensive experience preparing for and defending against these challenges. We understand the strategic and tactical implications that are particular to Abbreviated New Drug Application (ANDA) cases and use this knowledge to protect clients’ market opportunities, including in relation to pre-suit investigations, FDA strategy and related litigation, Patent Office proceedings, District Court litigations, and appeals. We leverage our extensive ANDA litigation experience to develop a case that accounts for multiple challengers presenting multiple theories.
Firm recognized by Law360 for major court victories and high-profile deals in the life sciences sector for the third consecutive year.
Latham litigators honored for successful outcomes in New York’s Appellate Division, First Department for Searchlight Capital Partners as well as at the US Internal Trade Commission on behalf of Serendia LLC.
Financial Times recognizes the firm’s strengths across metrics that assess legal industry leadership and strategic growth.